Collegium Pharmaceutical (NASDAQ:COLL) Announces Earnings Results, Beats Expectations By $0.09 EPS

Collegium Pharmaceutical (NASDAQ:COLL) released its quarterly earnings results on Thursday. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09, Zacks reports. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Collegium Pharmaceutical updated its FY 2025 guidance to EPS.

Collegium Pharmaceutical Trading Up 0.2 %

COLL opened at $28.42 on Friday. Collegium Pharmaceutical has a fifty-two week low of $27.84 and a fifty-two week high of $42.29. The company has a market cap of $916.55 million, a price-to-earnings ratio of 12.25 and a beta of 0.82. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a 50 day simple moving average of $30.88 and a 200 day simple moving average of $33.55.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on COLL. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Piper Sandler lowered their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

Insiders Place Their Bets

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total value of $908,600.00. Following the sale, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 3.98% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.